Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
University of British Columbia · Monash University · +11 more institutions
Abstract
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre phase II trials and a prospective province-wide blood biobanking program. ctDNA% correlates with serum and radiographic metrics of disease burden and is highest in patients with liver metastases. ctDNA% strongly predicts overall survival, progression-free survival, and treatment response…
Citation impact
- FWCI
- 29.21
- Percentile
- 100%
- References
- 83
Authors
39Topics & keywords
- Medicine
- Prostate cancer
- Internal medicine
- Oncology
- Liquid biopsy
- Genotyping
- Biomarker
- Circulating tumor DNA
- Good health and well-being